I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.

While some analysts say Donald Trump is a wild card when it comes to drug pricing, many argue his presidency would be more ...